Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End Users and Geographical Regions
Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.
The "Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill/Finish, Cryopreservation, Thawing, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain.
One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030.
Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies.
However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination.
Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.
Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality.
Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.
Scope of the Report
An insightful product competitiveness analysis, taking into consideration various relevant parameters, such as supplier power (based on the experience/expertise of the developer in this industry) and portfolio-related parameters, such as number of systems offered, cells supported, type of culture supported, scale of operation, applications, end users, support services offered, regulatory certifications/accreditations obtained and key product specifications.
Elaborate profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.
An analysis of the various partnerships pertaining to automated and closed cell therapy processing systems, which have been established since 2016, based on several parameters, such as year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner's focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.
A detailed assessment of the current market landscape, featuring an elaborate list of over 60 automated and closed systems, along with information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill/finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert system), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals/medical centers/clinics, research institutes/academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification/validation, maintenance, regulatory support and others) and regulatory certification/accreditations obtained (GMP/cGMP, GAMP, GCP, GTP/cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).
The report features detailed transcripts of interviews held with the following industry stakeholders:
Peter Molloy (Executive Vice President, Orgenesis) and Shimon Hassin (Chief Technology Officer, Orgenesis)
Jean Sebastien Parisse (Commercial Director, Aseptic Technologies)
Key Questions Answered
Which are the popular automated and closed systems commonly used for cell therapy processing?
Who are the leading industry and non-industry players in this domain?
What type of partnership models are commonly adopted by stakeholders in this industry?
Which players are likely to be potential partners of automated and closed system providers?
What is the current and likely future cost saving opportunities associated with use of automated and closed systems for cell therapy processing?
What are the key trends within the automated and closed cell therapy processing systems market?
How is the current and future market opportunity likely to be distributed across key market segments?
Companies Mentioned
3P Biopharmaceuticals
A*STAR's Institute of Molecular and Cell Biology
AbbVie
Accellix
Acer Therapeutics
Achilles Therapeutics
Activartis Biotech
Adaptimmune
Adicet Bio
Aduro Biotech
Adva Biotechnology
Advent Bioservices
AgenTus Therapeutics
Aglaris
AK (Suzhou) Biomedical
Aldagen
Allele Biotechnology & Pharmaceuticals
Allergan
Allife Medical Science and Technology
Allogene Therapeutics
Altor BioScience
AmerCare
Amgen
Amphera
Anhui Kedgene Biotechnology
ANI Pharmaceuticals
Anterogen
apceth Biopharma
Araymondlife
ARBELE
Argos Therapeutics
Asahi Glass Company
Aseptic Technologies
Astellas Pharma
Asterias Biotherapeutics
Astraveus
AstraZeneca
Asymptote
Atara Biotherapeutics
Athersys
Atlantic Bio GMP
ATLATL Innovation Cluster
Atreca
Aurora Biopharma
Autolus
AVAX Technologies
Basic Pharma
Batavia Bioservices
Bavarian Nordic
Baxalta
Baxter
Bayer
Beijing Biohealthcare Biotechnology
Beijing Doing Biomedical
Beijing Immunochina Medical Science & Technology
Beijing Sanwater Biological Technology
Beijing Tricision Biotherapeutics
Beike Biotechnology
Bellicum Pharmaceuticals
Bio Elpida
BioAtla
BioCardia
Biogen
Bioinova
BioNTech Innovative Manufacturing Services
Bio-Process Systems Alliance
BioRestorative Therapies
Biosafe
Biotec Services International
Bio-Techne
bluebird bio
Boehringer Ingelheim
Bone Therapeutics
BrainStorm Cell Therapeutics
Brammer Bio
Bristol Myers Squibb
BTI
Caladrius Biosciences
CANCER-ID
Capricor Therapeutics
Captain T Cell
CardioCell
Carina Biotech
CARsgen Therapeutics
CAR-T (Shanghai) Biotechnology
Cartherics
Celgene
Celixir
Cell and Gene Therapy Catapult
Cell Biotech
Cell Genesys
Cell Tech Pharmed
Cell Therapies
Cellectis
CELLforCURE
CellGenix
Cellin Technologies
Cellmed
CellPraxis
CellProtect Nordic Pharmaceuticals
CellProthera
Cellular Biomedicine Group
Cellular Therapeutics
Celularity
Celyad
Centre for Commercialization of Regenerative Medicine
Chengdu MedGenCell
CiMaas
Cognate BioServices
Cook MyoSite
Cord Blood Registry
Cordlife
Corestem
CRISPR Therapeutics
CRMI
Cryosite
Cytiva
Cytopeutics
Cytori Therapeutics
Cytosen Therapeutics
Cytovac
CyTuVax
Daiichi Sankyo
Daikyo Seiko
Danaher
DanDrit Biotech
DCPrime
Delta-Vir
DEMCON
Dendreon
DiscGenics
Draper
Eli Lilly
Endocyte
Esco Aster
Esco VacciXcell
Eureka Therapeutics
Eutilex
Ever Union Biotechnology
eXmoor Pharma Concepts
EXUMA Biotechnology
Fate Therapeutics
Ferrer Internacional
FIB Hospital Infantil Universitario Nino Jesus
Fibrocell Technologies
Five Prime Therapeutics
Flaskworks
FloDesign Sonics
Formula Pharmaceuticals
Fortress Biotech
Fred Hutchinson Cancer Research Center
Freeline
Fresenius Kabi
FUJIFILM Cellular Dynamics
FUJIFILM Diosynth Biotechnologies
Gadeta
Gamida Cell
GC Cell
G-Con Manufacturing
GE Healthcare
GE Medical Systems Trade & Development (Shanghai)
Genentech
Genzyme
GigaGen
Gilead Sciences
GlaxoSmithKline
Global Cell Med
Glycostem Therapeutics
GPB Scientific
Gracell Biotechnologies
Gradalis
Green Cross
GRI Bio
Guangzhou Trinomab Biotech
Haemonetics
Heat Biologics
Hebei Senlang Biotechnology
Hemostemix
HengRui YuanZheng Bio-Technology
Histocell
Histogenics
Hitachi Chemical Advanced Therapeutics Solutions
Holostem Terapieavanzate
Human Life CORD Japan
Hunan Zhaotai Yongren Biotech
iCarTAB BioMed
iCell Gene Therapeutics
Immatics
Immune Therapeutics
Immunicum
ImmunoCellular Therapeutics
Immunocore
Immunovative Therapies
IncoCell Tianjin
Incysus
Innovative Cellular Therapeutics
Inovio Pharmaceuticals
inRegen
Intellia Therapeutics
Intrexon
Invetech
Iovance Biotherapeutics
ISTO Technologies
Ivy Life Sciences
Janssen
Japan Tissue Engineering (J-TEC)
Johns Hopkins University
Johnson & Johnson
Juno Therapeutics
JW Biotechnology
JW CreaGene
KangStem Biotech
Kawasaki Heavy Industries
KBI Biopharma
Kiromic
Kite Pharma
Konkuk University
kSep Systems
Kuur Therapeutics
Legend Biotech
Leucid Bio
Lifecells
Lion TCR
Living Pharma
Longeveron
Lonza
Lorem Cytori
Lorem Vascular
Marino Biotechnology
Marker Therapeutics
MaSTherCell
Max Planck Institute for Dynamics of Complex Technical Systems
MaxCyte
MedCision
Medeor Therapeutics
Medigene
MEDINET
MEDIPOST
MedVax Technologies
Merck
Merck Serono
Mesoblast
MicrofluidX
Miltenyi Biotec
Minovia Therapeutics
MolecuVax
MolMed
Moraga Biotechnology
Multimmune
Mustang Bio
NantKwest
Neopharm
NewLink Genetics
Nikon CeLL innovation
Nkarta
Noga Therapeutics
Nohla Therapeutics
Noile-Immune Biotech
Northern Therapeutics
Northwest Biotherapeutics
Novadip Biosciences
Novartis
NovaRx
Novella Clinical
Novo Nordisk
Octane Biotech
OhioHealth
OiDE BetaRevive
Ompi
Oncobiomed
Opexa Therapeutics
Orchard Therapeutics
Orgenesis
Ori Biotech
Osiris Therapeutics
OSPIN
Oxford BioMedica
Oxford MEStar
Pall Corporation
Parker Institute for Cancer Immunotherapy
PDC*line Pharma
PersonGen BioTherapeutics
Pfizer
PharmaBio
PharmaCell
Pharmicell
Pinze Lifetechnology
Pique Therapeutics
Pluristem Therapeutics
Poseida Therapeutics
Praxis Pharmaceutical
Precision BioSciences
Pregene ShenZhen Biotechnology
Immutep
Promethera Biosciences
Regeneris Medical
Regeneron
Regeneus
ReNeuron
RHEACELL
Roche
Roslin Cells
Sangamo Therapeutics
Sanofi
Saronic Biotechnology
Sartorius
Sartorius Stedim Biotech
SCHOTT
Scinogy
Scinus Cell Expansion
Sclnow Biotechnology
Seattle Genetics
Seneca Biopharma
Sentien Biotechnologies
Servier
Shanghai Bioray Laboratory
Shanghai GeneChem
Shanghai Houchao Biotechnology
Shanghai iCELL Biotechnology
Shanghai Longyao Biotechnology
Shanghai Unicar-Therapy Bio-medicine Technology
Sheba Medical Center
Shenzhen BinDeBio
Shenzhen Hornetcorn Biotechnology
Shibuya
Shionogi
Shreedhar Instruments
Singota Solutions
Sinobioway Cell Therapy
SMT Bio
Sorrento Therapeutics
SOTIO
Southwest Research Institute
SQZ Biotech
Stafa Cellular Therapy
Stanford School of Medicine
Stem Cell Arabia
STEMCELL Technologies
Stemedica Cell Technologies
Stempeutics Research
Super-T Cell Cancer Company
Surface Oncology
Tactiva Therapeutics
Taiwan Bio Therapeutics
Takara Bio
Takeda Pharmaceuticals
TapImmune
Targazyme
TC BioPharm
TCR2 Therapeutics
Tella
Terumo BCT
Tessa Therapeutics
Teva Pharmaceutical Industries
TheraCell Advanced Biotechnology
Thermo Fisher Scientific
ThermoGenesis
Tianhe Stem Cell Biotechnologies
TiGenix
TILT Biotherapeutics
Tissue Genesis
Tmunity Therapeutics
TNK Therapeutics
TotipotentRX
TRACT Therapeutics
TrakCel
TransCure BioServices
Triumvira Immunologics
TVAX Biomedical
Shanghai Unicar Therapy Bio medicine Technology
Universal Cells
University of California, Davis
University Of North Carolina Lineberger Comprehensive Cancer Center
Unum Therapeutics
US Stem Cell
Vaccinogen
Vanrx Pharmasystems
Vericel
ViroMed
Viscofan BioEngineering
VivaBioCell
Volta Therapeutics
Waisman Biomanufacturing
WiSP Wissenschaftlicher Service Pharma
Wuhan Sian Medical Technology
WuXi AppTec
Xcelthera
Xellbiogene
XEME Biopharma
Yposkesi
Zelluna Immunotherapy
Zenith Technologies
Zimmer Biomet
Ziopharm Oncology
For more information about this report visit https://www.researchandmarkets.com/r/ly01kj
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900